Some HDAC inhibitors may be limited by more than epigenetics, raising new questions about how these cancer drugs really work

Some HDAC inhibitors may be limited by more than epigenetics, raising new questions about how these cancer drugs really work

Few ideas have been as influential in modern oncology as the notion that cancer can be treated not only by killing tumour cells directly, but also by changing how genes are regulated. In that context, histone deacetylase inhibitors, or HDAC inhibitors, gained prominence as a class of drugs aimed at epigenetic regulation — in other words, mechanisms that alter gene activity without changing the DNA sequence itself.

That model still matters. But the supplied evidence suggests it may be incomplete.

The safest reading of the material is that the activity of some HDAC inhibitors may be shaped not only by their classic epigenetic target effects, but also by unexpected mechanisms of drug handling, metabolism, and tumour resistance inside cancer cells. That does not mean the traditional epigenetic model is wrong. It suggests instead that the model may not fully explain why some of these drugs work, fail, or lose effectiveness in cancer.

The classic view: block HDACs and change gene expression

The traditional logic behind HDAC inhibitors is relatively straightforward. HDAC enzymes help remove acetyl groups from proteins, including histones. That process influences chromatin structure and, in turn, affects which genes are more or less active.

By inhibiting HDACs, these drugs can increase acetylation and alter gene-expression programs tied to proliferation, differentiation, apoptosis, and other processes that matter in cancer.

That framework remains valid and is still a major part of how these agents are understood. The problem is that it may simplify a drug class whose real biological behaviour appears to be more complicated.

A new twist: cancer cells may chemically inactivate some of these drugs

The most striking finding in the supplied evidence comes from a mechanistic study showing that METTL7A and METTL7B can confer resistance to thiol-based HDAC inhibitors. They do this by methylating and inactivating the zinc-binding thiol group, a chemically important part of the drug required for its activity.

That detail is technical, but conceptually it matters a great deal.

It suggests that, for at least some HDAC inhibitors, effectiveness depends not only on reaching the HDAC target and changing acetylation. It may also depend on whether the cancer cell can chemically disable the drug before it fully does its job.

In other words, some tumours may not simply be “resistant” in a vague, general sense. They may be actively neutralizing the drug through a very specific biochemical process.

Why this changes how researchers may need to think about HDAC inhibitors

If this mechanism really helps determine response, it forces a rethink of a comfortable assumption: that HDAC inhibitors can be understood mostly through their classical epigenetic target.

The newer view is broader. It includes at least three overlapping layers:

• the drug’s epigenetic target;
• the chemistry of the drug itself;
• and the way a cancer cell processes, modifies, or inactivates that molecule.

That may sound like a subtle laboratory distinction, but it changes the questions that matter in drug development. Instead of asking only, “Does this drug inhibit HDAC?”, researchers may also need to ask, “Can the cancer cell disable it first?”, “Which tumours express this resistance mechanism?”, and “Can future compounds be designed to avoid that vulnerability?”

The point may be especially important in solid tumours

The supplied evidence suggests this reconsideration may be especially relevant in solid tumours, where HDAC inhibitors have not always lived up to the promise implied by their biological rationale.

That matters because many cancer drugs look compelling in theory, show activity in model systems, and then deliver uneven results in the clinic. When that happens, the explanation often gets left at broad terms such as “tumour resistance” or “biological complexity”.

This newer work adds something more concrete: in at least some cases, there may be a drug-inactivation mechanism that limits activity from the start.

That does not solve the problem. But it makes the problem more specific — and potentially more actionable.

Even before this, HDAC inhibitors were already more complex than their label suggested

The broader review literature on romidepsin reinforces another important point: HDAC inhibitors were never fully reducible to a simple story about histone acetylation alone.

Review evidence suggests these drugs can act through multiple downstream pathways, including:

• apoptosis;
• immune modulation;
• cell-cycle disruption;
• proteostasis stress;
• and effects on the tumour microenvironment.

That matters because it shows the story was already more layered than the simplest epigenetic model implied. The newer finding does not overturn a perfectly settled framework so much as add to a picture that was already becoming more sophisticated.

A useful way to think about it is this: HDAC inhibitors do not stop being epigenetic drugs, but they may also be pharmacologically and biologically more diverse than the label alone suggests.

Rethinking mechanism does not mean rejecting epigenetics

That point is worth stressing to avoid overstatement.

The fact that some studies point to additional or unexpected mechanisms does not mean HDAC inhibitors “do not work through epigenetics” or that the classic theory was fundamentally mistaken. The more responsible interpretation is narrower: the classic model may be real, but incomplete.

In medicine, that is common. A drug may genuinely engage the target it was designed for while still having its effectiveness shaped by metabolism, intracellular transport, parallel signalling pathways, and adaptations inside diseased cells.

For HDAC inhibitors, that fuller picture now looks increasingly plausible.

The evidence has important limits

Even so, the limitations need to stay clear.

First, the new resistance mechanism appears most strongly supported for a subset of thiol-based HDAC inhibitors. That means it should not automatically be generalized to the entire drug class.

Second, one of the supplied articles is not actually about HDAC inhibitors, which makes the overall evidence set somewhat heterogeneous.

Third, much of the support here is mechanistic or review-based, rather than direct clinical proof that changing how these mechanisms are understood will improve patient outcomes.

That matters because in oncology, a compelling mechanism does not automatically translate into better treatment. Sometimes it leads to better drug design. Sometimes it simply explains, after the fact, why earlier therapies underperformed.

What this could mean for the future of cancer drug development

Even with those cautions, the scientific implications are meaningful. If some tumours can chemically inactivate certain HDAC inhibitors, that could influence:

• the design of newer compounds;
• the choice of drug combinations;
• the development of resistance biomarkers;
• and the selection of patients most likely to respond.

It may also help explain why drugs within the same family can behave differently in practice. Instead of treating all HDAC inhibitors as roughly interchangeable versions of the same idea, researchers may increasingly need to think of them as molecules with distinct vulnerabilities.

That shift in perspective could be valuable in a field where clinical translation has not always matched the original biological enthusiasm.

The balanced takeaway

The most responsible interpretation of the supplied evidence is that some HDAC inhibitors may have their effectiveness shaped not only by classic epigenetic target inhibition, but also by unexpected mechanisms of drug chemistry, metabolism, and tumour resistance.

The mechanistic finding involving METTL7A and METTL7B offers a concrete explanation for resistance to thiol-based HDAC inhibitors, showing that these enzymes can methylate and inactivate the zinc-binding thiol group needed for drug activity. At the same time, broader literature on romidepsin and related agents reinforces that HDAC inhibitors already appear to act through multiple biological routes beyond histone acetylation alone, including apoptosis, immune modulation, cell-cycle disruption, proteostasis stress, and effects on the tumour microenvironment.

But the limits remain important: the evidence is strongest for a subset of the class, part of the evidence base is heterogeneous, and there is not yet direct clinical proof that revising these mechanistic assumptions by itself improves outcomes for patients. It would also be misleading to suggest that HDAC inhibitors do not work through epigenetic regulation at all; the stronger conclusion is that the classic model likely does not tell the whole story.

If this line of research advances, it may do more than refine an academic theory. It could help explain why some epigenetic drugs disappoint, why others perform better than expected, and how future cancer therapies in this class might be made less vulnerable to subtle but powerful forms of tumour resistance.